Search results
Results from the WOW.Com Content Network
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.
“This research, which used human tissue and animals, shows that PIPE-307 has the potential to be used as a myelin repair treatment. But to really understand whether this drug will work we need ...
Clemastine, an antihistamine drug, has been studied for its potential to possibly promote remyelination and myelin repair in conditions like multiple sclerosis (MS). [ 21 ] [ 22 ] Early phase II clinical trials showed promise for promoting remyelination in patients with MS, with clemastine improving nerve conduction velocity in the optic nerve.
Increased myelin density in humans as a result of a prolonged myelination may, therefore, structure risk for myelin degeneration and dysfunction. Evolutionary considerations for the role of prolonged cortical myelination as a risk factor for demyelinating disease are particularly pertinent given that genetics and autoimmune deficiency ...
For premium support please call: 800-290-4726 more ways to reach us
Myelin's best known function is to increase the rate at which information, encoded as electrical charges, passes along the axon's length. Myelin achieves this by eliciting saltatory conduction. [1] Saltatory conduction refers to the fact that electrical impulses 'jump' along the axon, over long myelin sheaths, from one node of Ranvier to the next.
A new study explains how mitochondria act as “reservoirs” to store NAD for cells to use, which could help scientists come up with NAD-boosting therapies to combat aging and age-related diseases.
A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. Given its origin and behavior it is classified as a sarcoma. About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 8–13%. [2]